Preclinical safety evaluation of cerivastatin, a novel HMG-CoA reductase inhibitor

American Journal of Cardiology

Volumn 82, Issue 4 B, 1998, Pages 11J-17J

  Keutz, Eckhard Von ^a   Schlüter, Gerhard ^a  

^a BAYER AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CERIVASTATIN; MEVALONIC ACID;

ANIMAL EXPERIMENT; BRAIN HEMORRHAGE; CARCINOGENICITY; CATARACT; CONFERENCE PAPER; DOG; DOSE RESPONSE; DRUG DETERMINATION; DRUG SAFETY; GASTROINTESTINAL TOXICITY; MOUSE; MUTAGEN TESTING; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0344906091     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00424-X     Document Type: Conference Paper

References (27)

1. Shear C.L., Franklin F.A., Stinnett S., Hurley D.P., Bradford R.H., Chremos A.N., Nash D.T., Langendorfer A. Expanded clinical evaluation of lovastatin (EXCEL) study results. Circulation. 85:1992;1293-1303.
2. Gerson R.J., Allen H.L., Lankas G.R., MacDonald J.S., Alberts A.W., Bokelman D.L. The toxicity of a fluorinated-biphenyl HMG-CoA reductase inhibitor in beagle dogs. Fundam Appl Toxicol. 16:1991;320-329.
3. Gerson R.J., MacDonald J.S., Alberts A.W., Chen J., YudKovitz J.B., Greenspan M.D., Rubin L.F., Bokelman D.L. On the etiology of subcapsular lenticular opacities produced in dogs receiving HMG-CoA reductase inhibitors. Exp Eye Res. 50:1990;65-78.
4. MacDonald J.S., Gerson R.J., Kornbrust D.J., Kloss M.W., Prahalada S., Berry P.H., Alberts A.W., Bokelman D.L. Preclinical evaluation of lovastatin. Am J Cardiol. 62:(suppl):1988;16J-27J.
5. Gerson R.J., MacDonald J.S., Alberts A.W., Kornbrust D.J., Majka J.A., Stubbs R.J., Bokelman D.L. Animal safety and toxicology of simvastatin and related hydroxy-methylglutaryl-coenzyme A reductase inhibitors. Am J Med. 87:(suppl):1989;28S-38S.
6. Keim RG. Toxicology and carcinogenicity of pravastatin. FDA Endocrinologic and Metabolic Drugs Advisory Committee on Pravastatin. Miller Reporting Co., Washington DC, 1990.
7. Hartman H.A., Myers L.A., Evans M., Robinson R.L., Engstrom R.G., Tse F.L.S. The safety evaluation of fluvastatin, an HMG-CoA reductase inhibitor, in beagle dogs and rhesus monkeys. Fundam Appl Toxicol. 29:1996;48-62.
8. Walsh K.M., Albassam M.A., Clarke D.E. Subchronic toxicity of atorvastatin, a hydroxymethylglutaryl-coenzyme a reductase inhibitor, in beagle dogs. Toxicol Pathol. 24:1996;468-476.
9. Dobs A.S., Sarma P.S., Schteingart D. Long-term endocrine function in hypercholesterolemic patients treated with pravastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Metabolism. 42:1993;1146-1152.
10. Minsker D.H., MacDonald J.S., Robertson R.T., Bokelman D.L. Mevalonate supplementation in pregnant rats suppresses the teratogenicity of mevinolinic acid, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Teratology. 28:1983;449-456.
11. FDA. Summary basis for approval of NDA 20-261 (fluvastatin). Pharmacology Review of Amendment Conducted August, 1988. 1993.
12. Newman T.B., Hulley S.B. Carcinogenicity of lipid-lowering drugs. JAMA. 275:1996;55-60.
13. Angerbauer R., Bischoff H., Steinke W., Ritter W. BAY w 6228. Hypolipidemic HMG-CoA reductase inhibitor. Drugs Fut. 19:1994;537-541.
14. Schalke B.B., Schmidt B., Toyka K., Hartung H.P. Pravastatin-associated inflammatory myopathy. N Engl J Med. 327:1992;649-650.
15. Tobert J.A. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol. 62:1988;28-34.
16. Willis R.A., Folkers K., Tucker J., Ye C.Q., Xia L.J., Tamagawa H. Lovastatin decreases coenzyme Q levels in rats. Proc Natl Acad Sci USA. 87:1990;8928-8930.
17. Folkers K., Langsjoen P., Willis R., Richardson P., Xia L.J., Ye C.Q., Tamagawa H. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci USA. 87:1990;8931-8934.
18. Grinlanda G., Oradei A., Manto A. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors a double-blind, placebo-controlled study . J Clin Pharmacy. 33:1993;226-229.
19. Summary basis for approval of NDA 19-643 (lovastatin). Pharmacol Rev. 1987.
20. Summary basis for approval of NDA 19-898 (pravastatin). Pharmacol Rev. 1989.
21. Summary basis for approval of NDA 19-766 (simvastatin). Pharmacol Rev. 1990.
22. Physicians' Desk Reference, Edition 50. Montvale, NJ: Medical Economics Company, 1996.
23. Pierce I.L.R., Wysowski D.K., Gross T.P. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA. 264:1990;71-75.
24. Laaksonen R., Jokelainen K., Sahi T., Tikkanen M.J., Himberg J.J. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. Clin Pharmacol Ther. 57:1995;62-66.
25. Smith P.F., Eydelloth R.S., Grossmann S.J., Stubbs R.J., Schwartz M.S., Germershausen J.I., Vyas K.P., Kari P.H., MacDonald J.S. HMG-CoA reductase inhibitor-induced myopathy in the rat cyclosporine A interaction and mechanism studies . J Pharmacol Exp Ther. 257:1991;1225-1235.
26. Farnsworth W.H., Hoeg J.M., Maher M., Brittain E.H., Sherins R.J., Brewer H.B. Jr. Testicular function in Type II hyperlipoproteinemic patients treated with lovastatin (mevinolin) or neomycin. J Clin Endocrinol Metab. 65:1987;546-550.
27. Purvis K., Tollefsrud A., Rui H., Haug E., Norseth J., Viksmoen L., Ose L., Lund H. Short-term effects of treatment with simvastatin on testicular function in patients with heterozygous familial hypercholesterolaemia. Eur J Clin Pharmacol. 42:1992;61-64.